Stockreport

Travere Therapeutics Non-GAAP EPS of $0.59 beats by $0.68, revenue of $164.9M beats by $58.81M [Seeking Alpha]

Travere Therapeutics, Inc.  (TVTX) 
PDF More on Travere Therapeutics Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS Travere: No AdCom, No Problem - Targeting Big Revenues With [Read more]